Pancreatic Cancer & Pancreatic Endocrine Tumors

Foundations and mechanisms

Exocrine pancreatic cancer: origin, anatomy, and molecular pathogenesis

Most “pancreatic cancer” on USMLE Step 1 refers to pancreatic ductal adenocarcinoma, an aggressive malignant tumor arising from duct-forming exocrine epithelium. It accounts for approximately 85–90% of pancreatic malignancies. The pancreas is retroperitoneal; the head lies within the duodenal C-loop and is traversed by the distal common bile duct, whereas the body and tail extend toward the spleen. This anatomy explains classic presentations: tumors in the head, which comprise about 60–70% of cases, commonly obstruct the common bile duct and cause painless jaundice; body/tail tumors present later with vague pain and weight loss.

The dominant precursor lesion is pancreatic intraepithelial neoplasia (PanIN), a microscopic ductal lesion progressing from low-grade dysplasia to carcinoma. Less common macroscopic precursors include intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN). The key biologic theme is accumulation of driver mutations that promote autonomous growth, resistance to apoptosis, and stromal invasion.

Alteration	Approximate frequency in ductal adenocarcinoma	Mechanistic significance
KRAS activation	>90%	Constitutive RAS-MAPK and PI3K signaling; early event in PanIN
CDKN2A/p16 loss	~90%	Loss of G1/S checkpoint control via unchecked CDK4/6 activity
TP53 loss	~50–75%	Impaired DNA damage response and apoptosis; genomic instability
SMAD4/DPC4 loss	~50%	Disrupted TGF-β growth-inhibitory signaling; associated with invasion/metastasis
BRCA2, PALB2, ATM	Minority; enriched in familial disease	Defective homologous recombination DNA repair

Risk factors include cigarette smoking—the strongest modifiable risk factor, approximately doubling risk—chronic pancreatitis, hereditary pancreatitis, obesity, diabetes mellitus, older age, and familial cancer syndromes. High-yield inherited associations include BRCA2, Peutz-Jeghers syndrome due to STK11, Lynch syndrome, and familial atypical multiple mole melanoma syndrome due to CDKN2A.

Pathology and tumor biology

Ductal adenocarcinoma typically forms a hard, poorly defined, infiltrative mass with intense desmoplasia, meaning a dense fibrotic stromal response driven by tumor-associated fibroblasts, inflammatory cells, and extracellular matrix deposition. Microscopically, malignant gland-forming cells invade through pancreatic parenchyma, nerves, lymphatics, and blood vessels. Perineural invasion helps explain deep epigastric pain radiating to the back.

The tumor marker CA 19-9 is a sialylated Lewis blood group antigen. It is not useful for population screening because of limited specificity and false positives in cholestasis, pancreatitis, and other gastrointestinal cancers. In symptomatic patients, reported sensitivity is approximately 70–90% and specificity approximately 68–91%. About 5–10% of individuals are Lewis antigen-negative and cannot produce CA 19-9, causing false-negative results.

Core staging concepts

For Step 1, staging is most important conceptually: pancreatic ductal adenocarcinoma spreads by direct invasion into duodenum, stomach, bile duct, and major vessels; by lymphatic spread to peripancreatic and celiac nodes; and by hematogenous spread, especially to the liver and peritoneum. AJCC tumor size cutoffs are high yield: T1 ≤2 cm, T2 >2 cm and ≤4 cm, T3 >4 cm, and T4 involvement of major arteries such as the celiac axis, superior mesenteric artery, or common hepatic artery. Overall prognosis is poor, with contemporary 5-year survival for all stages roughly 10–13%.

Pancreatic neuroendocrine tumors: classification and hormone physiology

Pancreatic neuroendocrine tumors (PanNETs) arise from islet endocrine cells rather than ductal epithelium. They are far less common than ductal adenocarcinoma and may be functional, producing a hormone syndrome, or nonfunctional, presenting as a mass. Neuroendocrine cells characteristically express chromogranin A and synaptophysin. PanNETs may occur sporadically or with MEN1, caused by mutation of the MEN1 tumor suppressor gene encoding menin. MEN1 classically causes “3 Ps”: parathyroid tumors, pancreatic endocrine tumors, and pituitary adenomas.

Tumor	Hormone	Core mechanism and high-yield numbers
Insulinoma	Insulin	Autonomous insulin secretion causes fasting hypoglycemia. Whipple triad: symptoms, plasma glucose typically <55 mg/dL, relief with glucose. Endogenous source shows high insulin, high C-peptide, and high proinsulin.
Gastrinoma	Gastrin	Zollinger-Ellison syndrome: gastric acid hypersecretion, refractory peptic ulcers, diarrhea. Fasting gastrin often >1000 pg/mL with gastric pH <2.
Glucagonoma	Glucagon	Hyperglycemia, weight loss, anemia, and necrolytic migratory erythema. Excess glucagon promotes hepatic gluconeogenesis and lipolysis.
VIPoma	Vasoactive intestinal peptide	WDHA syndrome: watery diarrhea, hypokalemia, achlorhydria. Stool volumes may exceed 700 mL/day and persist with fasting.
Somatostatinoma	Somatostatin	Inhibits insulin, glucagon, CCK, gastrin, and pancreatic secretion; classically diabetes mellitus, gallstones, steatorrhea, and hypochlorhydria.

PanNET grade is based on proliferative activity rather than simply tumor size. A low mitotic rate and low Ki-67 index indicate well-differentiated behavior, whereas high Ki-67 indicates aggressive neuroendocrine carcinoma. Mechanistically, these tumors demonstrate endocrine granule secretion, hormone-specific systemic effects, and often a more indolent biology than ductal adenocarcinoma, though malignant potential varies substantially by subtype and size.

Clinical assessment and investigations

Clinical presentation: exocrine pancreatic cancer

Most pancreatic malignancies are pancreatic ductal adenocarcinomas (PDAC), typically arising in the pancreatic head. Early disease is often silent because the pancreas is retroperitoneal and tumors can grow before causing luminal obstruction. Classic symptoms reflect obstruction, invasion, cachexia, and paraneoplastic hypercoagulability.

• Painless jaundice: suggests obstruction of the distal common bile duct by a pancreatic head tumor. Laboratory pattern is cholestatic: increased conjugated bilirubin, alkaline phosphatase, and γ-glutamyl transferase.
• Courvoisier sign: palpable, nontender gallbladder with jaundice; classically suggests malignant biliary obstruction rather than gallstones.
• Weight loss, anorexia, early satiety: mediated by cancer-associated inflammation and altered metabolism.
• Epigastric pain radiating to the back: due to retroperitoneal invasion, especially with body/tail lesions.
• New-onset diabetes mellitus after age 50: can be a clue because pancreatic cancer impairs islet function and causes insulin resistance.
• Trousseau syndrome: migratory superficial thrombophlebitis due to tumor-associated tissue factor and mucin-mediated coagulation activation.

Clinical presentation: pancreatic neuroendocrine tumors

Pancreatic neuroendocrine tumors (PanNETs) arise from endocrine islet cells and may be functional or nonfunctional. Functional tumors produce hormone-mediated syndromes; nonfunctional tumors present from mass effect or metastases. Association with MEN1 should be considered, especially in young patients or those with hyperparathyroidism or pituitary tumors.

Tumor	Key presentation	High-yield diagnostic test
Insulinoma	Fasting hypoglycemia, confusion, diaphoresis, tremor; symptoms improve with glucose	72-hour fast showing glucose <55 mg/dL with inappropriately high insulin
Gastrinoma	Refractory peptic ulcers, diarrhea, abdominal pain; Zollinger-Ellison syndrome	Fasting gastrin >1000 pg/mL with gastric pH <2
VIPoma	Watery diarrhea, hypokalemia, achlorhydria; “WDHA syndrome”	VIP >75 pg/mL, often markedly elevated
Glucagonoma	Necrolytic migratory erythema, diabetes mellitus, weight loss, anemia	Glucagon typically >500 pg/mL
Somatostatinoma	Diabetes, gallstones, steatorrhea, hypochlorhydria	Elevated fasting somatostatin

Differential diagnosis

The clinical problem is usually either obstructive jaundice, pancreatic mass, or hormone-excess syndrome. Step 1 questions often distinguish malignant obstruction from benign biliary disease by pain, fever, gallbladder findings, and laboratory pattern.

Presentation	Important alternatives	Distinguishing clues
Painless jaundice	Pancreatic head cancer, cholangiocarcinoma, ampullary carcinoma	Conjugated hyperbilirubinemia; ductal dilation on imaging
Painful jaundice	Choledocholithiasis, acute cholangitis	Colicky pain; fever and right upper quadrant pain in cholangitis
Pancreatic mass	Chronic pancreatitis, pseudocyst, autoimmune pancreatitis, cystic neoplasm	History of alcohol use, recurrent pancreatitis, IgG4 disease, cystic imaging features
Hypoglycemia	Insulinoma, sulfonylurea use, exogenous insulin, adrenal insufficiency	C-peptide distinguishes endogenous from exogenous insulin

Investigations and interpretation

Laboratory studies

• Liver tests: pancreatic head tumors cause a cholestatic pattern. Direct bilirubin and alkaline phosphatase rise disproportionately compared with aminotransferases.
• CA 19-9: tumor-associated sialylated Lewis antigen. Normal is usually <37 U/mL. Sensitivity for symptomatic PDAC is approximately 70–90% and specificity 68–91%, but it is not a screening test. False positives occur in cholangitis, cholestasis, cirrhosis, and pancreatitis. False negatives occur in Lewis antigen-negative individuals, about 5–10% of the population.
• Chromogranin A: general PanNET marker, but false elevations occur with proton pump inhibitors, renal failure, and atrophic gastritis.

Imaging

• Right upper quadrant ultrasound: often first test for jaundice; detects biliary dilation and gallstones but is less sensitive for pancreatic body/tail lesions due to bowel gas.
• Pancreas-protocol contrast CT: key staging test for suspected PDAC. It uses thin cuts with arterial and portal venous phases to evaluate local vascular invasion, metastases, and resectability.
• MRI/MRCP: useful for ductal anatomy, cystic lesions, liver metastases, and patients with contrast limitations.
• Endoscopic ultrasound with fine-needle aspiration: highly sensitive for small lesions and provides tissue diagnosis. EUS can detect tumors <2 cm more reliably than transabdominal ultrasound.
• ERCP: visualizes and decompresses the biliary tree; mainly therapeutic or for duct sampling rather than initial diagnosis.
• Somatostatin receptor imaging: ⁶⁸Ga-DOTATATE PET/CT is highly sensitive for well-differentiated PanNETs because many express somatostatin receptor subtype 2.

Functional endocrine tumor testing

• Insulinoma: diagnose with Whipple triad: symptoms of hypoglycemia, plasma glucose typically <55 mg/dL, and relief after glucose. During a supervised 72-hour fast, endogenous hyperinsulinism is supported by insulin ≥3 µU/mL, C-peptide ≥0.6 ng/mL, proinsulin ≥5 pmol/L, suppressed β-hydroxybutyrate, and negative sulfonylurea screen.
• Gastrinoma: fasting serum gastrin >1000 pg/mL with gastric pH <2 is strongly suggestive. If gastrin is intermediate, secretin stimulation is used; paradoxical gastrin rise >120 pg/mL after IV secretin supports Zollinger-Ellison syndrome.
• VIPoma: secretory diarrhea persists during fasting; stool osmotic gap is low, usually <50 mOsm/kg.

Staging and resectability concepts

For PDAC, prognosis is driven by local vascular invasion and distant spread. CT assesses whether tumor contacts the celiac axis, superior mesenteric artery, portal vein, or superior mesenteric vein. Arterial encasement often means tumor contact >180° around the vessel circumference and usually indicates locally advanced disease. Common metastatic sites are liver and peritoneum. Population screening is not recommended; surveillance with MRI/MRCP and/or EUS is reserved for selected high-risk hereditary groups, often beginning at age 50 years or 10 years earlier than the youngest affected relative.

Management, pharmacology and procedures

Pancreatic ductal adenocarcinoma: management framework

Management is primarily determined by anatomic resectability, not by symptoms alone. Pancreatic ductal adenocarcinoma commonly presents late; only approximately 15–20% of patients have clearly resectable disease at diagnosis. Important vessels include the superior mesenteric artery (SMA), celiac axis, common hepatic artery, portal vein, and superior mesenteric vein (SMV). Cross-sectional staging is usually performed with a dedicated pancreatic-protocol CT.

Category	Key concept	Typical management
Resectable	No distant metastases; no major arterial encasement; reconstructible venous involvement absent or minimal	Surgery followed by adjuvant chemotherapy
Borderline resectable	Limited arterial contact or reconstructible SMV/portal vein involvement	Neoadjuvant chemotherapy ± radiation, then reassess for surgery
Locally advanced unresectable	Major arterial encasement or unreconstructible venous occlusion, but no distant metastases	Systemic chemotherapy; palliation; selected chemoradiation
Metastatic	Distant spread, classically liver or peritoneum	Palliative systemic therapy and symptom-directed procedures

Surgery and perioperative therapy

Tumors in the pancreatic head are treated with pancreaticoduodenectomy (Whipple procedure): removal of the pancreatic head, duodenum, gallbladder, distal common bile duct, and often distal stomach, followed by reconstruction. Tumors in the body or tail are treated with distal pancreatectomy, often with splenectomy. Surgical complications include pancreatic fistula, delayed gastric emptying, hemorrhage, infection, diabetes mellitus, and exocrine pancreatic insufficiency.

Adjuvant chemotherapy improves survival after resection. A high-yield landmark trial is PRODIGE 24/CCTG PA.6, in which modified FOLFIRINOX improved median overall survival to approximately 54.4 months versus 35.0 months with gemcitabine in fit patients after resection. Modified FOLFIRINOX combines 5-fluorouracil/leucovorin, irinotecan, and oxaliplatin. Mechanistically, 5-FU inhibits thymidylate synthase, irinotecan inhibits topoisomerase I, and oxaliplatin forms DNA cross-links. Toxicities include myelosuppression, diarrhea, mucositis, peripheral neuropathy, and nausea. Less fit patients may receive gemcitabine-based therapy; gemcitabine is a cytidine analog that inhibits DNA synthesis.

Advanced disease and palliation

For metastatic pancreatic cancer, systemic regimens include FOLFIRINOX for patients with good performance status and gemcitabine plus nab-paclitaxel. Nab-paclitaxel stabilizes microtubules and prevents mitotic spindle disassembly; neuropathy and myelosuppression are common. In germline BRCA1/BRCA2 or PALB2-mutated tumors, platinum sensitivity is important, and maintenance olaparib, a PARP inhibitor, may be used after response to platinum therapy; PARP inhibition exploits defective homologous recombination repair.

• Obstructive jaundice: managed with endoscopic retrograde cholangiopancreatography (ERCP) and biliary stent placement. Metal stents have longer patency than plastic stents and are favored when life expectancy is months.
• Gastric outlet obstruction: treated with duodenal stenting or surgical gastrojejunostomy.
• Pain: stepwise analgesia; severe epigastric pain radiating to the back may improve with celiac plexus block/neurolysis.
• Exocrine pancreatic insufficiency: pancreatic enzyme replacement, commonly pancrelipase 25,000–50,000 units of lipase with meals and smaller doses with snacks; acid suppression may improve enzyme activity.
• Follow-up marker: CA 19-9 is often followed after therapy; normal is typically <37 U/mL. It is not a screening test and may be falsely low in Lewis antigen-negative individuals.

Pancreatic neuroendocrine tumors: acute and long-term management

Pancreatic neuroendocrine tumors arise from islet endocrine cells and may be functional or nonfunctional. Management depends on hormone syndrome, tumor grade, metastatic burden, and expression of somatostatin receptors. Functional syndromes require immediate correction of hormone-mediated physiology before definitive tumor therapy.

Tumor	Acute management	Key pharmacology
Insulinoma	Treat hypoglycemia with oral glucose if awake or IV dextrose if severe; frequent carbohydrates	Diazoxide opens KATP channels, hyperpolarizing beta cells and decreasing insulin release; octreotide may help but can worsen hypoglycemia if glucagon is suppressed
Gastrinoma	Control acid hypersecretion and peptic ulcers	High-dose proton pump inhibitors, e.g., omeprazole 40–60 mg/day or higher; PPIs irreversibly inhibit gastric H+/K+-ATPase
VIPoma	Aggressive IV fluids and potassium replacement for watery diarrhea, hypokalemia, achlorhydria	Octreotide decreases VIP secretion and intestinal fluid secretion
Glucagonoma	Treat diabetes, weight loss, thrombosis risk, and nutritional deficiencies	Somatostatin analogs decrease hormone secretion; replete amino acids, zinc, and nutrients

Somatostatin analogs are central drugs for many functional tumors and somatostatin receptor-positive metastatic neuroendocrine tumors. Octreotide is a somatostatin analog with a plasma half-life of about 90–120 minutes; long-acting release formulations are given intramuscularly every 4 weeks. Lanreotide is another long-acting analog. These drugs inhibit release of insulin, glucagon, gastrin, VIP, serotonin, and other peptides by decreasing intracellular cAMP and calcium-mediated exocytosis. Adverse effects include gallstones, steatorrhea, glucose dysregulation, abdominal cramping, and bradycardia.

Definitive and advanced therapies for pancreatic neuroendocrine tumors

Localized insulinomas are often benign and treated with surgical enucleation or limited pancreatic resection. Larger, malignant, multifocal, or MEN1-associated tumors may require formal pancreatic resection and lymph node assessment. Gastrinomas may be associated with MEN1; therefore, clinicians also evaluate for hyperparathyroidism and pituitary disease.

For unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors, options include somatostatin analogs, liver-directed therapy for hepatic metastases, targeted therapy, cytotoxic chemotherapy, and peptide receptor radionuclide therapy. Everolimus inhibits mTOR, decreasing growth signaling; adverse effects include stomatitis, hyperglycemia, hyperlipidemia, pneumonitis, and immunosuppression. Sunitinib inhibits multiple receptor tyrosine kinases including VEGFR and PDGFR; adverse effects include hypertension, hand-foot syndrome, diarrhea, hypothyroidism, and cardiotoxicity.

Peptide receptor radionuclide therapy uses a somatostatin analog linked to a radioactive isotope, such as ¹⁷⁷Lu-DOTATATE, to deliver beta radiation to somatostatin receptor-positive tumor cells. The NETTER-1 trial in midgut neuroendocrine tumors showed markedly improved progression-free survival with ¹⁷⁷Lu-DOTATATE versus high-dose octreotide, supporting this receptor-targeted principle. Follow-up commonly includes symptom assessment, cross-sectional imaging, somatostatin receptor imaging when relevant, and biochemical markers such as chromogranin A, though chromogranin A can be falsely elevated by proton pump inhibitors and renal insufficiency.

Exam controversies and advanced synthesis

Pancreatic ductal adenocarcinoma: why “early detection” remains difficult

Pancreatic ductal adenocarcinoma (PDAC) is biologically aggressive because driver mutations accumulate silently in pancreatic intraepithelial neoplasia: KRAS activation is early, followed by loss of tumor suppressors such as CDKN2A, TP53, and SMAD4. Symptoms usually appear only after invasion, biliary obstruction, or metastasis. This explains a major exam controversy: routine population screening is not recommended, despite poor prognosis, because prevalence is low and available tests lack adequate positive predictive value.

Test/marker	High-yield numbers	Major pitfalls
CA 19-9	Normal usually <37 U/mL; sensitivity about 79–81%, specificity about 82–90% in symptomatic patients	False elevation with cholestasis, cholangitis, cirrhosis; false negative in Lewis antigen-negative patients, who cannot synthesize CA 19-9
Pancreas-protocol CT	Sensitivity commonly about 89–97% for pancreatic mass detection	May miss small lesions; must assess vascular involvement, not just mass presence
EUS-FNA	Sensitivity about 85–92%, specificity about 96–98%	Operator-dependent; useful when CT is equivocal or tissue confirmation is needed

Guidelines generally restrict surveillance to high-risk individuals, such as those with Peutz-Jeghers syndrome, hereditary pancreatitis, familial pancreatic cancer kindreds, or pathogenic germline variants such as CDKN2A, BRCA2, PALB2, ATM, or Lynch-associated genes. Surveillance typically uses MRI/MRCP and/or endoscopic ultrasound, often starting at age 50 years or 10 years earlier than the youngest affected relative; Peutz-Jeghers may begin around age 35–40, and CDKN2A around age 40. For Step 1, the principle is more important than the exact protocol: screen only when pretest probability is high.

Resectability, staging, and trial-based therapy: know the concepts, not oncology minutiae

PDAC staging integrates tumor size, nodal disease, metastasis, and vascular invasion. In AJCC-style anatomic thinking, T1 is ≤2 cm, T2 is >2 to ≤4 cm, T3 is >4 cm, and T4 involves major arteries such as the celiac axis or superior mesenteric artery. Clinically, tumors are often categorized as resectable, borderline resectable, locally advanced unresectable, or metastatic. The key mechanistic issue is whether the tumor encases or invades major vessels, especially the superior mesenteric artery, celiac axis, portal vein, and superior mesenteric vein.

Landmark trials are not heavily tested on Step 1, but they help contextualize why modern regimens appear in vignettes. In metastatic PDAC, FOLFIRINOX improved median overall survival to about 11.1 months versus 6.8 months with gemcitabine alone, but with greater toxicity. Gemcitabine plus nab-paclitaxel improved survival to about 8.5 months versus 6.7 months. In the adjuvant setting after resection, the PRODIGE 24/CCTG PA.6 trial showed modified FOLFIRINOX median overall survival about 54.4 months versus 35.0 months with gemcitabine. For Step 1, remember the pharmacologic classes: 5-fluorouracil inhibits thymidylate synthase, irinotecan inhibits topoisomerase I, oxaliplatin forms DNA crosslinks, and gemcitabine is a cytidine analog inhibiting DNA synthesis.

Pancreatic neuroendocrine tumors: classification prevents common errors

Pancreatic neuroendocrine tumors (PanNETs) arise from endocrine cells and are distinct from PDAC. They may be functional, producing hormone syndromes, or nonfunctional, presenting by mass effect or metastasis. Their grade is based on proliferation, not simply size.

Grade	Ki-67 index	Mitotic rate	Implication
G1	<3%	<2 per 10 high-power fields	Well-differentiated, slower growth
G2	3–20%	2–20 per 10 high-power fields	Intermediate behavior
G3	>20%	>20 per 10 high-power fields	High-grade; distinguish well-differentiated NET from poorly differentiated neuroendocrine carcinoma

Functional diagnostic thresholds are highly testable. Insulinoma causes fasting hypoglycemia with Whipple triad; during a supervised fast, glucose is typically <55 mg/dL with inappropriately high insulin ≥3 μU/mL, C-peptide ≥0.6 ng/mL, and proinsulin ≥5 pmol/L. Gastrinoma causes Zollinger-Ellison syndrome; fasting gastrin >1000 pg/mL with gastric pH <2 is strongly suggestive. VIPoma produces watery diarrhea, hypokalemia, and achlorhydria, often with VIP >75 pg/mL. Glucagonoma classically causes necrolytic migratory erythema, diabetes, weight loss, and glucagon often >500 pg/mL.

Therapeutic mechanisms that clarify exam vignettes

Somatostatin analogs reduce hormone secretion and can slow tumor growth in somatostatin-receptor-positive NETs. Typical doses include octreotide 50–100 μg subcutaneously every 8 hours for acute symptom control, octreotide LAR 20–30 mg intramuscularly every 4 weeks, or lanreotide 120 mg deep subcutaneously every 4 weeks. The CLARINET trial supported lanreotide for antiproliferative benefit in enteropancreatic NETs. Everolimus 10 mg orally daily inhibits mTOR signaling, and sunitinib 37.5 mg orally daily inhibits receptor tyrosine kinases including VEGFR. Lu-177 dotatate peptide receptor radionuclide therapy delivers targeted beta radiation to somatostatin-receptor-positive tumors; the NETTER-1 trial demonstrated markedly improved progression-free survival in midgut NETs.

High-yield pitfalls

• Courvoisier sign: painless jaundice plus palpable gallbladder suggests malignant obstruction, classically pancreatic head cancer, not gallstones.
• Trousseau syndrome: migratory thrombophlebitis from tumor-associated hypercoagulability is classically linked to pancreatic adenocarcinoma.
• MEN1: “3 Ps” are parathyroid, pituitary, and pancreatic endocrine tumors; gastrinomas are often duodenal and multiple.
• CA 19-9 is not a screening test; use it mainly for disease burden or recurrence trends in known PDAC.
• PDAC and PanNETs are different diseases: PDAC is exocrine ductal, desmoplastic, and usually lethal; PanNETs are endocrine, graded by Ki-67, and may present with hormone excess.